Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Rodriguez A, Lorza L, Martín A, Coria E, López-Guillermo A, Salar A, José Lahuerta J; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.

Hematol Oncol Stem Cell Ther. 2019 Jul 9. pii: S1658-3876(19)30052-4. doi: 10.1016/j.hemonc.2019.06.001. [Epub ahead of print]

2.

Multiscale constitutive model with progressive recruitment for nanofibrous scaffolds.

Caballero DE, Montini-Ballarin F, Gimenez JM, Urquiza SA.

J Mech Behav Biomed Mater. 2019 Oct;98:225-234. doi: 10.1016/j.jmbbm.2019.06.017. Epub 2019 Jun 27.

PMID:
31271979
3.

Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.

López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA.

Biol Blood Marrow Transplant. 2019 May 3. pii: S1083-8791(19)30282-4. doi: 10.1016/j.bbmt.2019.04.026. [Epub ahead of print]

PMID:
31054983
4.

Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.

Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D.

Bone Marrow Transplant. 2019 Jul;54(7):1176. doi: 10.1038/s41409-019-0471-y.

PMID:
30733543
5.

3D biosensors in advanced medical diagnostics of high mortality diseases.

Rebelo R, Barbosa AI, Caballero D, Kwon IK, Oliveira JM, Kundu SC, Reis RL, Correlo VM.

Biosens Bioelectron. 2019 Apr 1;130:20-39. doi: 10.1016/j.bios.2018.12.057. Epub 2019 Jan 11. Review.

PMID:
30716590
6.

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators.

J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.

PMID:
30707661
7.

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.

Redondo AM, Valcárcel D, González-Rodríguez AP, Suárez-Lledó M, Bello JL, Canales M, Gayoso J, Colorado M, Jarque I, Del Campo R, Arranz R, Terol MJ, Rifón JJ, Rodríguez MJ, Ramírez MJ, Castro N, Sánchez A, López-Jiménez J, Montes-Moreno S, Briones J, López A, Palomera L, López-Guillermo A, Caballero D, Martín A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO).

Br J Haematol. 2019 Mar;184(5):797-807. doi: 10.1111/bjh.15713. Epub 2018 Dec 12.

PMID:
30548583
8.

Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.

Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D.

Bone Marrow Transplant. 2019 Jul;54(7):1133-1137. doi: 10.1038/s41409-018-0422-z. Epub 2018 Dec 13. No abstract available. Erratum in: Bone Marrow Transplant. 2019 Feb 7;:.

PMID:
30546069
9.

Classifying different Iberian pig genetic lines by applying chemical-instrumental parameters of dry-cured Iberian shoulders.

Caballero D, Asensio M, Fernández C, Martín N, Silva A.

J Food Sci Technol. 2018 Nov;55(11):4589-4599. doi: 10.1007/s13197-018-3396-3. Epub 2018 Sep 1.

PMID:
30333655
10.

Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy.

Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault A, Caballero D, Harron R, Stathopoulou TR, Massey C, Shelton JM, Bassel-Duby R, Piercy RJ, Olson EN.

Science. 2018 Oct 5;362(6410):86-91. doi: 10.1126/science.aau1549. Epub 2018 Aug 30.

11.

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.

Hematol Oncol. 2018 Dec;36(5):765-772. doi: 10.1002/hon.2553. Epub 2018 Sep 12. No abstract available.

PMID:
30129233
12.

Sensitivity to Conflict between Visual Touch and Tactile Touch.

Caballero DE, Rombokas E.

IEEE Trans Haptics. 2019 Jan-Mar;12(1):78-86. doi: 10.1109/TOH.2018.2859940. Epub 2018 Jul 25.

PMID:
30047898
13.

Directed Flow of Micromotors through Alignment Interactions with Micropatterned Ratchets.

Katuri J, Caballero D, Voituriez R, Samitier J, Sanchez S.

ACS Nano. 2018 Jul 24;12(7):7282-7291. doi: 10.1021/acsnano.8b03494. Epub 2018 Jul 2.

PMID:
29949338
14.

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G.

J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.

PMID:
29851546
15.

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.

Afram G, Simón JAP, Remberger M, Caballero-Velázquez T, Martino R, Piñana JL, Ringden O, Esquirol A, Lopez-Corral L, Garcia I, López-Godino O, Sierra J, Caballero D, Ljungman P, Vazquez L, Hägglund H.

Med Oncol. 2018 Apr 25;35(6):79. doi: 10.1007/s12032-018-1127-2.

16.

A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.

Pardal E, Díez Baeza E, Salas Q, García T, Sancho JM, Monzón E, Moraleda JM, Córdoba R, de la Cruz F, Queizán JA, Rodríguez MJ, Navarro B, Hernández JA, Díez R, Vahi M, Viguria MC, Canales M, Peñarrubia MJ, González-López TJ, Montes-Moreno S, González-Barca E, Caballero D, Martín A; GELTAMO Spanish Collaborative Group.

Am J Hematol. 2018 Jul;93(7):867-873. doi: 10.1002/ajh.25107. Epub 2018 May 6.

17.

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.

Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M.

Leukemia. 2018 Aug;32(8):1799-1803. doi: 10.1038/s41375-018-0023-2. Epub 2018 Feb 2. No abstract available.

18.

Near-infrared spectroscopy-based analysis to study sensory parameters on pork loins as affected by cooking methods and conditions.

González-Mohino A, Antequera T, Ventanas S, Caballero D, Mir-Bel J, Pérez-Palacios T.

J Sci Food Agric. 2018 Aug;98(11):4227-4236. doi: 10.1002/jsfa.8944. Epub 2018 Mar 22.

PMID:
29406611
19.

Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Hernández-Garcia MT, Novelli S, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.

Bone Marrow Transplant. 2018 Jun;53(6):780-783. doi: 10.1038/s41409-018-0096-6. Epub 2018 Jan 23. No abstract available.

PMID:
29362504
20.

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez-Malaver FJ, Valcárcel D, Solano C, López-Corral L, Sierra J, Perales MA.

Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2.

21.

Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galego A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Coria E, Rodriguez A, Martín A, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative study group.

Cancer Med. 2017 Dec;6(12):2766-2774. doi: 10.1002/cam4.1217. Epub 2017 Oct 26.

22.

Organ-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient.

Caballero D, Kaushik S, Correlo VM, Oliveira JM, Reis RL, Kundu SC.

Biomaterials. 2017 Dec;149:98-115. doi: 10.1016/j.biomaterials.2017.10.005. Epub 2017 Oct 3. Review.

PMID:
29024838
23.

Tumour-vessel-on-a-chip models for drug delivery.

Caballero D, Blackburn SM, de Pablo M, Samitier J, Albertazzi L.

Lab Chip. 2017 Nov 7;17(22):3760-3771. doi: 10.1039/c7lc00574a. Review.

PMID:
28861562
24.

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C.

Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11. No abstract available.

25.

Prediction of pork quality parameters by applying fractals and data mining on MRI.

Caballero D, Pérez-Palacios T, Caro A, Amigo JM, Dahl AB, ErsbØll BK, Antequera T.

Food Res Int. 2017 Sep;99(Pt 1):739-747. doi: 10.1016/j.foodres.2017.06.048. Epub 2017 Jun 22.

PMID:
28784539
26.

A Novel Role for RARα Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening.

Lee SJ, Mahankali M, Bitar A, Zou H, Chao E, Nguyen H, Gonzalez J, Caballero D, Hull M, Wang D, Schultz PG, Shen W.

Sci Rep. 2017 Jul 19;7(1):5824. doi: 10.1038/s41598-017-05163-w.

27.

Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null mice.

Caballero D, Li Y, Fetene J, Ponsetto J, Chen A, Zhu C, Braddock DT, Bergwitz C.

PLoS One. 2017 Jul 13;12(7):e0180098. doi: 10.1371/journal.pone.0180098. eCollection 2017.

28.

Unmet needs in the scientific approach to older patients with lymphoma.

Bron D, Aurer I, André MPE, Bonnet C, Caballero D, Falandry C, Kimby E, Soubeyran P, Zucca E, Bosly A, Coiffier B; European Lymphoma Institute (ELI) Group and the EHA SWG “Aging and Hematology”.

Haematologica. 2017 Jun;102(6):972-975. doi: 10.3324/haematol.2017.167619. Review. No abstract available.

29.

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.

Hess G, Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Caballero D, Joao C, Witzens-Harig M, Bence-Bruckler I, Cho SG, Zhou W, Goldberg JD, Trambitas C, Enny C, Vermeulen J, Traina S, Chiou CF, Diels J, Dreyling M.

Leuk Lymphoma. 2017 Dec;58(12):2824-2832. doi: 10.1080/10428194.2017.1326034. Epub 2017 May 30.

PMID:
28556689
30.

Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, López Jiménez J, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1631-1640. doi: 10.1016/j.bbmt.2017.05.021. Epub 2017 May 19.

31.

18F-FDG PET/CT in the clinical management of patients with lymphoma.

Tamayo P, Martín A, Díaz L, Cabrero M, García R, García-Talavera P, Caballero D.

Rev Esp Med Nucl Imagen Mol. 2017 Sep - Oct;36(5):312-321. doi: 10.1016/j.remn.2017.03.004. Epub 2017 May 5. Review. English, Spanish.

PMID:
28483374
32.

Response of Npt2a knockout mice to dietary calcium and phosphorus.

Li Y, Caballero D, Ponsetto J, Chen A, Zhu C, Guo J, Demay M, Jüppner H, Bergwitz C.

PLoS One. 2017 Apr 27;12(4):e0176232. doi: 10.1371/journal.pone.0176232. eCollection 2017.

33.

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B.

J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20.

PMID:
28426350
34.

A randomized, double-blinded, controlled trial of the effects of fluid rate and/or presence of dextrose in intravenous fluids on the labor course of nulliparas.

Fong A, Serra AE, Caballero D, Garite TJ, Shrivastava VK.

Am J Obstet Gynecol. 2017 Aug;217(2):208.e1-208.e7. doi: 10.1016/j.ajog.2017.03.010. Epub 2017 Mar 18.

PMID:
28322776
35.

Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.

Sorigue M, Mercadal S, Alonso S, Fernández-Álvarez R, García O, Moreno M, Pomares H, Alcoceba M, González-García E, Motlló C, González-Barca E, Martin A, Sureda A, Caballero D, Ribera JM, Sancho JM.

Hematol Oncol. 2017 Dec;35(4):520-527. doi: 10.1002/hon.2378. Epub 2017 Feb 3. Erratum in: Hematol Oncol. 2019 Feb;37(1):114.

PMID:
28156010
36.

Topological Control of Extracellular Matrix Growth: A Native-Like Model for Cell Morphodynamics Studies.

Caballero D, Samitier J.

ACS Appl Mater Interfaces. 2017 Feb 1;9(4):4159-4170. doi: 10.1021/acsami.6b13063. Epub 2017 Jan 18.

PMID:
28068057
37.

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B.

Cancer Med. 2017 Jan;6(1):36-44. doi: 10.1002/cam4.939. Epub 2016 Dec 16.

38.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J.

Bone Marrow Transplant. 2017 Mar;52(3):372-380. doi: 10.1038/bmt.2016.282. Epub 2016 Dec 12.

PMID:
27941763
39.

Non-destructive analysis of sensory traits of dry-cured loins by MRI-computer vision techniques and data mining.

Caballero D, Antequera T, Caro A, Ávila MDM, G Rodríguez P, Perez-Palacios T.

J Sci Food Agric. 2017 Jul;97(9):2942-2952. doi: 10.1002/jsfa.8132. Epub 2016 Dec 7.

PMID:
27861925
40.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA.

Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7.

PMID:
27819684
41.

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.

Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA.

Bone Marrow Transplant. 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. Epub 2016 Jun 13. No abstract available.

PMID:
27295268
42.

Impaired urinary osteopontin excretion in Npt2a-/- mice.

Caballero D, Li Y, Ponsetto J, Zhu C, Bergwitz C.

Am J Physiol Renal Physiol. 2017 Jan 1;312(1):F77-F83. doi: 10.1152/ajprenal.00367.2016. Epub 2016 Oct 26.

43.

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.

Cabrero M, Martin A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D.

Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. Epub 2016 Oct 19.

44.

Motion in microfluidic ratchets.

Caballero D, Katuri J, Samitier J, Sánchez S.

Lab Chip. 2016 Nov 15;16(23):4477-4481.

45.

Ordering Single Cells and Single Embryos in 3D Confinement: A New Device for High Content Screening.

Wollrab V, Caballero D, Thiagarajan R, Riveline D.

J Vis Exp. 2016 Sep 18;(115). doi: 10.3791/51880.

46.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Lopez-Corral L, Solano C, Armand P, Pérez-Simon JA.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1808-1815. doi: 10.1016/j.bbmt.2016.07.006. Epub 2016 Jul 25.

47.

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.

Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau ME, d'Amore F, Haioun C, Thieblemont C, González-Barca E, García CG, Johnson PW, van Imhoff GW, Ng T, Dwyer K, Morschhauser F.

Haematologica. 2016 Oct;101(10):e407-e410. Epub 2016 Jul 14. No abstract available.

48.

Steric interactions determine side-chain conformations in protein cores.

Caballero D, Virrueta A, O'Hern CS, Regan L.

Protein Eng Des Sel. 2016 Sep;29(9):367-376. doi: 10.1093/protein/gzw027. Epub 2016 Jul 14.

PMID:
27416747
49.

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.

Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B.

Hematol Oncol. 2017 Dec;35(4):914-917. doi: 10.1002/hon.2320. Epub 2016 Jul 12. No abstract available.

50.

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.

Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G, Berge C, Sahin D, Press O, Sehn L.

Leuk Lymphoma. 2017 Feb;58(2):372-381. Epub 2016 Jun 24.

PMID:
27339738

Supplemental Content

Loading ...
Support Center